ライフサイエンスコーパス: chronic kidney disease

1 nd 1.07 [1.02-1.11] for acute kidney injury-/chronic kidney disease-).

2 disease-; and 1.5 L for acute kidney injury-/chronic kidney disease-.

3 ogression of acute kidney injury to advanced chronic kidney disease.

4 is associated with increased cancer risk and chronic kidney disease.

5 creased risk for developing hypertension and chronic kidney disease.

6 known pro-inflammatory, prognostic marker in chronic kidney disease.

7 tus, established cardiovascular disease, and chronic kidney disease.

8 nent source of oxidative stress in acute and chronic kidney disease.

9 um term, it inhibited the progression toward chronic kidney disease.

10 mptoms and signs in people with any stage of chronic kidney disease.

11 easing its cleavage, a possible treatment of chronic kidney disease.

12 ate and mineral homeostasis in health and in chronic kidney disease.

13 abolic abnormalities including patients with chronic kidney disease.

14 The primary outcome was the occurrence of chronic kidney disease.

15 ts are preserved, and perhaps exaggerated in chronic kidney disease.

16 isease, stroke, diabetes, heart failure, and chronic kidney disease.

17 Twenty-one children (18%) had chronic kidney disease.

18 ng YLL rates from interpersonal violence and chronic kidney disease.

19 ients with a history of heart failure and/or chronic kidney disease.

20 s comes with an increased risk of developing chronic kidney disease.

21 idney fibrosis, which is a major hallmark of chronic kidney disease.

22 clines and contributes to the progression of chronic kidney disease.

23 s influence on initiation and progression of chronic kidney disease.

24 ght in turn contribute to the progression of chronic kidney disease.

25 somal-dominant syndromic form of progressive chronic kidney disease.

26 d among non-dialysis-dependent patients with chronic kidney disease.

27 and so-called uremic toxins accumulating in chronic kidney disease.

28 , likely contributing to cachexia in CHF and chronic kidney disease.

29 as a new therapeutic target in patients with chronic kidney disease.

30 immunosuppression, chronic liver disease, or chronic kidney disease.

31 ficantly except in one patient with stage IV chronic kidney disease.

32 sult in an increasing and cumulative risk of chronic kidney disease.

33 metabolic diseases like gout, diabetes, and chronic kidney disease.

34 nal function in non-transplant patients with chronic kidney disease.

35 eading to the development and progression of chronic kidney disease.

36 with HCV genotype 1 infection and stage 4-5 chronic kidney disease.

37 and arteriosclerosis in ApoE(-/-) mice with chronic kidney disease.

38 25 patients (57.9%), of whom 679 (44.5%) had chronic kidney disease.

39 ients with a history of heart failure and/or chronic kidney disease.

40 ion of diabetes mellitus and a major type of chronic kidney disease.

41 olves kidney podocyte dysfunction and causes chronic kidney disease.

42 nal cardiovascular risk factors, stroke, and chronic kidney disease.

43 itiation periods compared with those without chronic kidney disease.

44 ere significantly more likely to have severe chronic kidney disease.

45 adults, and those with diabetes mellitus or chronic kidney disease.

46 tus, established cardiovascular disease, and chronic kidney disease.

47 new target for the treatment of fibrosis in chronic kidney disease.

48 in AKI and their persistence in progressive chronic kidney disease.

49 ontributes to extraskeletal complications in chronic kidney disease.

50 ialysis, and durable loss of renal function [chronic kidney disease]).

51 failure (40.7%-56.1%), acute (5.9%-20.1%) or chronic kidney disease (1.1%-16.4%), fluid and electroly

52 +; 1.09 [1.05-1.13] for acute kidney injury-/chronic kidney disease+; 1.05 [1.03-1.08] for acute kidn

53 o, 1.06 [1.03-1.09] for acute kidney injury+/chronic kidney disease+; 1.09 [1.05-1.13] for acute kidn

54 Chronic kidney disease (10.4% vs. 5.6%; aOR, 1.49 [CI, 1

55 e likely to have major comorbidity including chronic kidney disease (25.2% versus 13.2%; P=0.02) and

56 e identified: 5.9 L for acute kidney injury+/chronic kidney disease+; 3.8 L for acute kidney injury-/

57 ney disease+; 3.8 L for acute kidney injury-/chronic kidney disease+; 4.3 L for acute kidney injury+/

58 Some patients will develop chronic kidney disease after a hospitalization with acut

59 r 23 (FGF23) increase early during acute and chronic kidney disease and are associated with adverse o

60 oteins increase in plasma and tissues during chronic kidney disease and are associated with deleterio

61 ysplasia (RHD) are major causes of pediatric chronic kidney disease and are highly genetically hetero

62 was associated with certain risk factors for chronic kidney disease and certain kidney-biopsy finding

63 ransient ischemic attack, vascular diseases, chronic kidney disease and chronic obstructive pulmonary

64 Patients had stage 4 or 5 chronic kidney disease and either had received no previo

65 Patients with chronic kidney disease and end-stage renal disease are a

66 Sevelamer is widely used in chronic kidney disease and end-stage renal disease patie

67 ON) is the most prevalent cause of pediatric chronic kidney disease and end-stage renal disease.

68 logic response in patients with stage 4 or 5 chronic kidney disease and HCV infection.

69 Conclusions and Relevance: Chronic kidney disease and hypertension are common 5 yea

70 eded to ascertain resolution or worsening of chronic kidney disease and hypertension.

71 ard Glassock discuss diagnostic criteria for chronic kidney disease and implications for disease prog

72 Although obesity is associated with risk for chronic kidney disease and improved survival, less is kn

73 Reduced glomerular filtration rate defines chronic kidney disease and is associated with cardiovasc

74 initiative-to include patients with advanced chronic kidney disease and kidney transplant recipients.

75 Kidney fibrosis is a hallmark of chronic kidney disease and leads to extracellular matrix

76 African Americans develop chronic kidney disease and pulmonary hypertension (PH) a

77 yclonal lymphoproliferation, and significant chronic kidney disease and requiring long-term immunosup

78 assessed despite strong correlation between chronic kidney disease and survival.

79 ascular events and death among patients with chronic kidney disease and the general population.

80 ould be prescribed to patients with advanced chronic kidney disease and those on dialysis.

81 t human urinary protein, plays a key role in chronic kidney diseases and is a promising therapeutic t

82 cohorts exclusively enrolling patients with chronic kidney disease), and at least 50 peripheral arte

83 omorbidities (anemia, diabetes mellitus, and chronic kidney disease), and the use of anticoagulation

84 sion, lupus erythematosus, recent pneumonia, chronic kidney disease, and active cancer, but confoundi

85 and non-cardiac variables (body-mass index, chronic kidney disease, and chronic obstructive pulmonar

86 ranges from bone marrow failure syndromes to chronic kidney disease, and from nutritional deficiencie

87 ulmonary hypertension, leg ulcers, priapism, chronic kidney disease, and large-artery ischemic stroke

88 tcomes as cardiovascular disease, blindness, chronic kidney disease, and limb amputation.

89 al solid organ transplant recipients develop chronic kidney disease, and some develop end-stage renal

90 +; 1.05 [1.03-1.08] for acute kidney injury+/chronic kidney disease-; and 1.07 [1.02-1.11] for acute

91 ney disease+; 4.3 L for acute kidney injury+/chronic kidney disease-; and 1.5 L for acute kidney inju

92 y disease, heart failure, diabetes mellitus, chronic kidney disease, anemia, coagulopathy, obesity, m

93 The Chronic Kidney Disease Antidepressant Sertraline Trial (

94 In particular, patients with chronic kidney disease are at high risk for adverse even

95 Diabetes mellitus, heart failure (HF), and chronic kidney disease are common comorbidities, but ove

96 gnificant contributor to mortality in native chronic kidney disease as well as cardiovascular mortali

97 s therefore ideal for patients with advanced chronic kidney disease, as patients with end-stage renal

98 llitus, hypertension, and advanced stages of chronic kidney disease at baseline.

99 co's progress against communicable diseases, chronic kidney disease burden rapidly climbed, with age-

100 n corrects or improves many complications of chronic kidney disease, but its impact on disordered min

101 EPCs) remain in the kidneys of patients with chronic kidney disease, but these cells do not produce s

102 er, higher Charlson Comorbidity Index score, chronic kidney disease, cancer, respiratory infection, v

103 has been proposed to underlie diseases like chronic kidney disease, cancers, and psoriasis that othe

104 ere significant predictors for ADHF included chronic kidney disease, cardiovascular disease, age>/=75

105 rd ratios and better risk discrimination for chronic kidney disease, cardiovascular disease, peripher

106 ifferent in terms of risk discrimination for chronic kidney disease, cardiovascular outcomes, or mort

107 tant nephrotic syndrome (SRNS) causes 15% of chronic kidney disease cases.

108 ciated with iron deficiency anaemia--notably chronic kidney disease, chronic heart failure, cancer, a

109 nd carbon monoxide (CO) and risk of incident chronic kidney disease, chronic kidney disease progressi

110 -AIDS comorbidities (cardiovascular disease, chronic kidney disease, chronic lung disease, liver dise

111 Of 4 patients with chronic kidney disease (CKD) > stage 2 at short-term fol

112 vided into subgroups of those with stage 1-2 chronic kidney disease (CKD) (estimated glomerular filtr

113 The risk for chronic kidney disease (CKD) among obese persons without

114 sorders of glucose homeostasis are common in chronic kidney disease (CKD) and are associated with inc

115 order (MDD) is prevalent among patients with chronic kidney disease (CKD) and is associated with morb

116 Cognitive impairment is very common in chronic kidney disease (CKD) and is strongly associated

117 ast growth factor 23 (FGF23) are elevated in chronic kidney disease (CKD) and strongly associated wit

118 Complex human traits such as chronic kidney disease (CKD) are a major health and fina

119 Patients with chronic kidney disease (CKD) are at an increased risk of

120 Background: Trends in the prevalence of chronic kidney disease (CKD) are important for health ca

121 ct changes in renal function in an all-cause chronic kidney disease (CKD) cohort.

122 Chronic kidney disease (CKD) has a prevalence of approxi

123 Chronic kidney disease (CKD) has been associated with im

124 Although the effect of HIF activation in chronic kidney disease (CKD) has been widely evaluated,

125 The definition and classification of chronic kidney disease (CKD) have evolved over time, but

126 patitis C virus (HCV)-infected patients with chronic kidney disease (CKD) have rarely been studied be

127 Conventional methods to diagnose and monitor chronic kidney disease (CKD) in children, such as creati

128 We assessed the risk of chronic kidney disease (CKD) in chronic hepatitis C viru

129 ator receptor (suPAR) independently predicts chronic kidney disease (CKD) incidence and progression.

130 Complications of chronic kidney disease (CKD) include weak bones and incr

131 Diabetes mellitus (DM) and chronic kidney disease (CKD) increase mortality in patie

132 Chronic kidney disease (CKD) is a complex gene-environme

133 Chronic kidney disease (CKD) is a prevalent cause of mor

134 Chronic kidney disease (CKD) is a well-known risk factor

135 Chronic kidney disease (CKD) is commonly managed in prim

136 Chronic kidney disease (CKD) is defined by reduced estim

137 related quality of life (HRQOL) in anemia of chronic kidney disease (CKD) is unclear.

138 For chronic kidney disease (CKD) monitoring in primary care,

139 hat metabolic alterations play a key role in chronic kidney disease (CKD) pathogenesis.

140 n 50 de novo renal transplant recipients, 50 chronic kidney disease (CKD) patients (n = 50) matched f

141 Chronic kidney disease (CKD) predicts mortality after ab

142 The patient with chronic kidney disease (CKD) represents an extreme model

143 To reduce over-diagnosis of chronic kidney disease (CKD) resulting from the inaccura

144 During chronic kidney disease (CKD) there is a dysregulation of

145 notypic manifestation in the transition from chronic kidney disease (CKD) to end-stage renal disease

146 actors related to mortality of patients with chronic kidney disease (CKD) were investigated to find o

147 ificance of the reported higher incidence of chronic kidney disease (CKD) with intensive systolic blo

148 e and poses a risk of developing progressive chronic kidney disease (CKD) with no definitive treatmen

149 cirrhosis, but less likely to have stage 3-5 chronic kidney disease (CKD), alcohol or drug abuse or d

150 levels are highly elevated in patients with chronic kidney disease (CKD), and it is likely that FGF2

151 occurrence of type 2 diabetes mellitus (DM), chronic kidney disease (CKD), and treated hypertension (

152 osterone antagonists slow the progression of chronic kidney disease (CKD), but their use is limited b

153 with type 2 diabetes and moderate to severe chronic kidney disease (CKD), congestive heart failure (

154 agnostics may be advantageous in adults with chronic kidney disease (CKD), in whom the cause of kidne

155 rocess affecting kidneys during aging and in chronic kidney disease (CKD), regardless of cause.

156 r implicated in the onset and progression of chronic kidney disease (CKD), such as focal segmental gl

157 examined the association of HF with incident chronic kidney disease (CKD), the composite of incident

158 mmatory disease process, often progresses to chronic kidney disease (CKD), with no available effectiv

159 The mechanisms underlying chronic kidney disease (CKD)-associated higher risks for

160 The chronic kidney disease (CKD)-mineral bone disorder (MBD)

161 or a cohesive plan to address the problem of chronic kidney disease (CKD).

162 ranscatheter aortic valve replacement having chronic kidney disease (CKD).

163 of morbidity and mortality in patients with chronic kidney disease (CKD).

164 ly prevalent in dialysis-naive patients with chronic kidney disease (CKD).

165 cells that contributes to the development of chronic kidney disease (CKD).

166 ey also serve as a good model of progressive chronic kidney disease (CKD).

167 nd tissue remodeling that is associated with chronic kidney disease (CKD).

168 sized that a decrease in AIF would result in chronic kidney disease (CKD).

169 nflammation and dysfunction in patients with chronic kidney disease (CKD).

170 tant nephrotic syndrome (SRNS) causes 15% of chronic kidney disease (CKD).

171 a measure of kidney function used to define chronic kidney disease (CKD).

172 impact on long-term outcomes is uncertain in chronic kidney disease (CKD).

173 ate of survival of MALA induced in mice with chronic kidney disease (CKD).

174 normotension (control) or with hypertensive chronic kidney disease (CKD).

175 ransplantation (KT) may restore fertility in chronic kidney disease (CKD).

176 associated with cardiovascular morbidity in chronic kidney disease (CKD).

177 nfected individuals are at increased risk of chronic kidney disease (CKD).

178 that they may be associated with the risk of chronic kidney disease (CKD).

179 he failure of a variety of organs, including chronic kidney disease (CKD).

180 central pathogenic process in progression of chronic kidney disease (CKD).

181 ability of renal elasticity in patients with chronic kidney disease (CKD).

182 scores for cardiovascular disease (CVD) and chronic kidney disease (CKD, defined as confirmed estima

183 s closely associated with the progression of chronic kidney diseases (CKD) by producing renal tubuloi

184 nal mechanisms is involved in development of chronic kidney diseases (CKD).

185 INTERPRETATION: Even mild-to-moderate chronic kidney disease conferred increased risk of incid

186 jury, AKI was associated with development of chronic kidney disease, conversion to chronic dialysis,

187 tive data on NOACs in patients with advanced chronic kidney disease (creatinine clearance <30 ml/min)

188 We established the Chronic Kidney Disease database CKDdb, an integrated and

189 Advanced chronic kidney disease developed in 408 (2.7%) of 9973 p

190 sent important risk factors for postischemic chronic kidney disease development.

191 uffered more often from atrial fibrillation, chronic kidney disease, diabetes mellitus, and dyslipide

192 Yet rising adult mortality rates from chronic kidney disease, diabetes, cirrhosis, and, since

193 idence of peripheral artery disease (PAD) in chronic kidney disease differs according to sex and age.

194 less than 60 mL/min per 1.73 m(2), incident chronic kidney disease, eGFR decline of 30% or more, and

195 s associated with increased risk of incident chronic kidney disease, eGFR decline, and end-stage rena

196 Loss of podocytes leads to chronic kidney disease ending in end stage renal disease

197 with HCV genotype 1 infection and stage 4-5 chronic kidney disease enrolled at 68 centres worldwide

198 Body surface area (BSA)-adjusted chronic kidney disease epidemiology (CKD-EPI) was the mo

199 Using Chronic Kidney Disease Epidemiology Collaboration (CKD-E

200 With the use of the Chronic Kidney Disease Epidemiology Collaboration equati

201 eGFR was assessed by using the Chronic Kidney Disease Epidemiology Collaboration equati

202 15 to 59 mL/min/1.73 m2, estimated with the Chronic Kidney Disease Epidemiology Collaboration equati

203 it, and eGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration equati

204 estimated with both the Cockcroft-Gault and Chronic Kidney Disease Epidemiology Collaboration equati

205 The Chronic Kidney Disease Epidemiology Collaboration, prefe

206 le Modification of Diet in Renal Disease and chronic kidney disease epidemiology with "true," or meas

207 al to a nephrologist should be considered if chronic kidney disease (estimated glomerular filtration

208 nt and joint associations of two measures of chronic kidney disease (estimated glomerular filtration

209 loss effects are attenuated in patients with chronic kidney disease (estimated glomerular filtration

210 increased AKI among these participants with chronic kidney disease (estimated glomerular filtration

211 analyzed African Americans participants with chronic kidney disease (estimated glomerular filtration

212 laboratory data was able to predict advanced chronic kidney disease following hospitalization with ac

213 se-2 (TG2) is a new anti-fibrotic target for chronic kidney disease, for its role in altering the ext

214 ine disease history, except for diabetes and chronic kidney disease, for which smaller, but significa

215 Patients with chronic kidney disease had higher rates of both hyperkal

216 Females with chronic kidney disease have a higher PAD risk compared w

217 le of tubular hypoxia in the pathogenesis of chronic kidney disease have given us pause to reconsider

218 atients with both HCV infection and advanced chronic kidney disease have limited treatment options.

219 e younger, more likely to have hypertension, chronic kidney disease, HF, coronary heart disease, and

220 y under the ACC/AHA guidelines only had less chronic kidney disease; however, these individuals were

221 ral infection (HR 2.11, 95 % CI: 1.88-2.36), chronic kidney disease (HR 1.59, 95 % CI: 1.33-1.90), ch

222 nsapical TAVR (HR, 1.21; 95% CI, 1.05-1.39), chronic kidney disease (HR, 1.20; 95% CI, 1.04-1.39), ch

223 Data from the CKD in Children Study Chronic Kidney Disease in Children (CKiD) Study indicate

224 residual risk factor for cardiovascular and chronic kidney disease in patients with type 1 diabetes

225 re to antiretrovirals and the development of chronic kidney disease in people with initially normal r

226 .1-8.9), 285 (1%) of 23,905 people developed chronic kidney disease (incidence 1.76 per 1000 person-y

227 rmal renal function, the annual incidence of chronic kidney disease increased for up to 6 years of ex

228 ducible factor (HIF)-1 mediates hypoxia- and chronic kidney disease-induced fibrotic events.

229 Some evidence suggests that chronic kidney disease is a risk factor for lower-extrem

230 Chronic kidney disease is a significant complication aft

231 of diabetes mellitus in patients with HF and chronic kidney disease is complex, and these patients ar

232 me antiretrovirals used in HIV infection and chronic kidney disease is cumulative is a controversial

233 ABSTRACT: Chronic kidney disease is strongly associated with a dec

234 ; however, potential involvement of PPM1A in chronic kidney disease is unknown.

235 l fibrosis, a common pathological feature of chronic kidney diseases, is often associated with apopto

236 ntil the occurrence of one of the following: chronic kidney disease; last eGFR measurement; Feb 1, 20

237 Patients with previous VTE, chronic kidney disease, liver disease, cancer, and throm

238 Patients with previous VTE, chronic kidney disease, liver disease, cancer, and throm

239 ALYs were diabetes, ischaemic heart disease, chronic kidney disease, low back and neck pain, and depr

240 , hyperlipidemia, cardiovascular events, and chronic kidney disease) (mean, 7.7 years).

241 Both chronic kidney disease measures were independently assoc

242 We investigated the modifications of chronic kidney disease-mineral and bone disorder with a

243 The management of chronic kidney disease-mineral and bone disorders has re

244 sease as well as cardiovascular mortality in chronic kidney disease more than doubles that of the gen

245 s with Cox regression, young age, absence of chronic kidney disease, negative lymphovascular invasion

246 therosclerosis, hypertension, heart failure, chronic kidney disease, obesity, and type 2 diabetes mel

247 ty and mortality, such as diabetes mellitus, chronic kidney disease, obstructive sleep apnea, etc.

248 n rate < 45 mL/min/1.73 m(2)) or progressive chronic kidney disease occurs after treatment, especiall

249 h advanced congestive heart failure (CHF) or chronic kidney disease often have increased angiotensin

250 interaction between acute kidney injury and chronic kidney disease on cumulative fluid balance (p =0

251 fferential effect of acute kidney injury and chronic kidney disease on the association between cumula

252 no interaction of serum erythropoietin with chronic kidney disease or anemia (P > 0.50).

253 rial, 8561 patients with type 2 diabetes and chronic kidney disease or cardiovascular disease were ra

254 (ARBs) in patients with type 2 diabetes and chronic kidney disease or cardiovascular disease.

255 (e.g., NSAID prescription in a patient with chronic kidney disease or coprescription of an NSAID and

256 ory of stroke (OR, 0.55; 95% CI, 0.45-0.69), chronic kidney disease (OR, 0.46; 95% CI, 0.36-0.59), ch

257 hypertension (OR, 1.95; 95% CI, 1.03-3.70), chronic kidney disease (OR, 2.05; 95% CI, 1.15-3.64), cr

258 .0%) had established cardiovascular disease, chronic kidney disease, or both.

259 .2%) had established cardiovascular disease, chronic kidney disease, or both.

260 ndency only for patients with prior advanced chronic kidney disease (p = 0.04).

261 s a multicenter, prospective cohort study of chronic kidney disease participants.

262 rt failure (HF) admission or mortality among chronic kidney disease patients, including patients with

263 Among African Americans with chronic kidney disease, PH, which is likely pulmonary ve

264 members of the general population and to the chronic kidney disease population, the risk was lowest i

265 in the general population and highest in the chronic kidney disease population.

266 rtality regardless of acute kidney injury or chronic kidney disease presence.

267 sis of international cohorts included in the Chronic Kidney Disease Prognosis Consortium (baseline me

268 Renal fibrosis is the common pathway of most chronic kidney disease progression to end-stage renal fa

269 and risk of incident chronic kidney disease, chronic kidney disease progression, and end-stage renal

270 myocardial infarction (MI) in patients with chronic kidney disease requiring long-term dialysis (sta

271 atitis C virus (HCV) infection and stage 4-5 chronic kidney disease resulted in a high rate of virolo

272 p = 0.02) and higher risk for patients with chronic kidney disease (RR: 1.29; p = 0.03) and with new

273 e albumin to creatinine ratio >30 mg/g), and chronic kidney disease (serum creatinine estimated glome

274 phrotoxic antiretrovirals or at high risk of chronic kidney disease should be closely monitored.

275 ange proteinuria in 20/46 (43%) patients and chronic kidney disease stage 3 or above in 42/49 (86%) p

276 nzapine, and quetiapine had reduced rates of chronic kidney disease stage 3 or more severe, following

277 22 patients with chronic kidney disease stage 5 undergoing intermittent h

278 The change of chronic kidney disease stages were recorded and compared

279 Measurements: Chronic kidney disease (stages 3 and 4) was defined as a

280 pital mortality based on acute kidney injury/chronic kidney disease status, underpinning the heteroge

281 mated from cystatin C well matched follow-up chronic kidney disease status.

282 p < 0.001), and in each acute kidney injury/chronic kidney disease subgroup (adjusted odds ratio, 1.

283 on is more prevalent among patients who have chronic kidney disease than among those who do not have

284 rge body of evidence showing the pandemic of chronic kidney disease, the impact of pre-operative kidn

285 In end-stage chronic kidney disease, the option of organ transplantat

286 Adverse outcomes were chronic kidney disease, thyroid disease, hypercalcemia,

287 The C-statistic for incident chronic kidney disease was 0.636 for ADA fasting glucose

288 An increased risk of incident chronic kidney disease was associated with an IQR increa

289 Chronic kidney disease was defined as confirmed (>3 mont

290 Chronic kidney disease was defined as estimated glomerul

291 Advanced chronic kidney disease was defined by a sustained reduct

292 Although the absolute number of new cases of chronic kidney disease was modest, treatment with these

293 All-cause death and incident chronic kidney disease were secondary outcomes.

294 A total of 2,632 patients, 1,211 with chronic kidney disease, were followed up until hospital

295 t failure patients have a high prevalence of chronic kidney disease, which further heightens the risk

296 Patients with chronic kidney disease who also have HCV infection are a

297 n, integrating discussion of proteinuria and chronic kidney disease with emphasis on pathogenesis, hi

298 diovascular disease in native and transplant chronic kidney disease, with potential application to me

299 end-stage renal disease than those who have chronic kidney disease without HCV infection.

300 e >/=75 years, prior cardiovascular disease, chronic kidney disease, women, black race, and 3 levels